Since the first chimeric antigen receptor (CAR) T-cell therapy was approved by the US Food and Drug Administration (FDA) for the treatment of large B-cell lymphoma (LBCL) in the third or later line of therapy, there has been significant development in the field. There are now 3 approved CAR T-cell therapies for various subtypes of LBCL, and these immunotherapies are now moving into earlier treatment, with axi-cel and liso-cel both FDA approved in the second-line setting. At the same time, researchers have made tremendous strides in managing the hallmark toxicities of CAR T-cell therapy like cytokine release syndrome (CRS) and neurologic events, opening the possibility for this therapy to move safely beyond academic medical centers and into outpatient settings.
The educational activity features expert faculty evaluating the current treatment landscape of CAR T-cell therapy for relapsed/refractory LBCL, highlighting evidence set to transform clinical practice particularly in the second-line setting. A three-dimensional mechanism of action animation video clip will illustrate similarities and differences within the structure and costimulatory domains of different CAR T-cell therapies. This activity will serve as the foundation for a robust panel discussion activity entitled Paradigm Shifts in CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: A Video Panel Discussion, where an expert faculty panel will provide their insights on how this new emerging evidence can and should be considered for real-world clinical practice.